INO

1.78

2.30% 0.04

Dopo l'orario di chiusura: 1.79 0.01 +0.56%

Inovio Pharmaceuticals Inc (INO)

Panoramica Notizia Cronologia dei prezzi Catena di opzioni Financials Forum Previsione Frazionamento azionario

Precedente Chiudi:

$1.74

Aprire:

$1.74

Volume 24 ore:

505.31K

Relative Volume:

0.71

Capitalizzazione di mercato:

$64.91M

Reddito:

$832.00K

Utile/perdita netta:

$-135.12M

Rapporto P/E:

-0.2923

EPS:

-6.09

Flusso di cassa netto:

$-124.69M

1 W Prestazione:

+0.56%

1M Prestazione:

-7.29%

6M Prestazione:

-68.99%

1 anno Prestazione:

-81.61%

Intervallo 1D:

$1.74

$1.9192

Intervallo di 1 settimana:

$1.675

$1.9192

Portata 52W:

$1.42

$13.44

Inovio Pharmaceuticals Inc Stock (INO) Company Profile

Nome

Inovio Pharmaceuticals Inc

Settore

Healthcare (1182)

Industria

Biotechnology (677)

Telefono

(858) 410-3134

Indirizzo

660 W. GERMANTOWN PIKE, PLYMOUTH MEETING, PA

Dipendente

134

Cinguettio

@inoviopharma

Prossima data di guadagno

2024-11-07

Ultimi documenti SEC

INO's Discussions on Twitter

Confronta INO con altri titoli

Azioni	Prezzo	Cap. di mercato	Reddito	Reddito netto	Flusso di cassa	EPS
INO Inovio Pharmaceuticals Inc	1.78	64.91M	832.00K	-135.12M	-124.69M	-6.09
VRTX Vertex Pharmaceuticals Inc	477.52	127.47B	11.02B	-535.60M	-978.00M	-2.20
REGN Regeneron Pharmaceuticals Inc	561.49	62.43B	14.20B	4.41B	3.54B	38.28
ARGX Argen X Se Adr	595.70	37.03B	2.19B	833.04M	-1.28B	12.71
ALNY Alnylam Pharmaceuticals Inc	232.75	31.06B	2.25B	-278.16M	-42.59M	-2.17
ONC Beigene Ltd Adr	229.22	26.16B	3.81B	-644.79M	-669.77M	-6.24

Inovio Pharmaceuticals Inc Stock (INO) Upgrades & Downgrades

Data	Azione	Analista	Modifica della valutazione
2024-05-14	Iniziato	Stephens	Overweight
2024-01-25	Aggiornamento	Oppenheimer	Perform → Outperform
2022-11-09	Downgrade	Maxim Group	Buy → Hold
2022-11-01	Downgrade	BofA Securities	Neutral → Underperform
2022-07-19	Ripresa	RBC Capital Mkts	Sector Perform
2022-05-11	Downgrade	Oppenheimer	Outperform → Perform
2022-01-21	Aggiornamento	BofA Securities	Underperform → Neutral
2021-12-29	Ripresa	Jefferies	Hold
2021-09-10	Downgrade	BofA Securities	Neutral → Underperform
2021-06-24	Iniziato	Jefferies	Hold
2021-03-23	Iniziato	BofA Securities	Neutral
2021-02-12	Iniziato	Oppenheimer	Outperform
2020-11-17	Downgrade	ROTH Capital	Neutral → Sell
2020-11-10	Aggiornamento	ROTH Capital	Sell → Neutral
2020-09-28	Downgrade	Cantor Fitzgerald	Overweight → Neutral
2020-09-28	Aggiornamento	Maxim Group	Hold → Buy
2020-07-01	Downgrade	Maxim Group	Buy → Hold
2020-07-01	Downgrade	ROTH Capital	Neutral → Sell
2020-06-29	Downgrade	H.C. Wainwright	Buy → Neutral
2020-06-26	Downgrade	Stifel	Buy → Hold
2020-05-21	Iniziato	The Benchmark Company	Buy
2020-04-30	Downgrade	ROTH Capital	Buy → Neutral
2020-03-13	Downgrade	Piper Sandler	Overweight → Neutral
2020-03-13	Downgrade	RBC Capital Mkts	Outperform → Sector Perform
2019-12-19	Iniziato	ROTH Capital	Buy
2018-02-15	Reiterato	Maxim Group	Buy
2017-10-18	Iniziato	RBC Capital Mkts	Outperform
2017-09-06	Iniziato	Citigroup	Buy
2017-06-08	Aggiornamento	Piper Jaffray	Neutral → Overweight
2017-05-24	Reiterato	Maxim Group	Buy
2017-03-16	Aggiornamento	Maxim Group	Hold → Buy
2017-03-16	Downgrade	Piper Jaffray	Overweight → Neutral

Mostra tutto

Inovio Pharmaceuticals Inc Borsa (INO) Ultime notizie

05:27 AM

Inovio Pharmaceuticals Inc. stock outperforms competitors on strong trading day - MarketWatch

05:27 AM

07:40 AM

Bet on These 5 Top-Ranked Stocks With Rising P/E - Yahoo Finance

07:40 AM

Apr 17, 2025

Immunology Data Shows INOVIO's INO-3107 Induced Expansion of New Clonal T Cells That Infiltrate Airway Tissue and Correspond With Reduction of Surgeries for RRP Patients Observed in Phase 1/2 Trial - ADVFN

Apr 17, 2025

Inovio Pharmaceuticals Inc. stock underperforms Thursday when compared to competitors despite daily gains - MarketWatch

Apr 17, 2025

Apr 16, 2025

Inovio Pharmaceuticals Inc. stock underperforms Wednesday when compared to competitors - MarketWatch

Apr 16, 2025

Apr 11, 2025

Inovio Pharmaceuticals Inc. stock rises Friday, still underperforms market - MarketWatch

Apr 11, 2025

INOVIO to Highlight Breakthrough Immunotherapy Data at AACR Conference - MSN

Apr 11, 2025

INOVIO to Showcase Breakthrough Data on INO-3107 at Major Industry Conferences - MyChesCo

Apr 11, 2025

Apr 10, 2025

Inovio Pharmaceuticals Inc. stock rises Wednesday, still underperforms market - MarketWatch

Apr 09, 2025

INOVIO to Present at Upcoming Scientific Conferences | INO Stock News - GuruFocus

Apr 09, 2025

INOVIO to Present at Upcoming Scientific Conferences - Longview News-Journal

Apr 09, 2025

INOVIO's Breakthrough: 72% Success in HPV TreatmentMultiple Conference Spotlights - Stock Titan

Apr 09, 2025

Apr 08, 2025

Inovio Pharmaceuticals Inc. stock underperforms Tuesday when compared to competitors - MarketWatch

Apr 08, 2025

Apr 07, 2025

Inovio stock touches 52-week low at $1.47 amid market challenges By Investing.com - Investing.com South Africa

Apr 07, 2025

Inovio stock touches 52-week low at $1.47 amid market challenges - Investing.com Australia

Apr 07, 2025

Apr 04, 2025

Inovio Pharmaceuticals Inc. stock outperforms competitors despite losses on the day - MarketWatch

Apr 04, 2025

Inovio Pharmaceuticals to Host Third Quarter 2013 Earnings Webcast Live on Tuesday, November 12, 2013 - ACCESS Newswire

Apr 04, 2025

Apr 02, 2025

HPV Market to Reach $10.8 Bn, Globally, by 2031 at 12.4% CAGR | - openPR.com

Apr 02, 2025

Apr 01, 2025

Down -11.41% in 4 Weeks, Here's Why You Should You Buy the Dip in Inovio (INO) - Yahoo Finance

Apr 01, 2025

Mar 31, 2025

Inovio Pharmaceuticals Inc. stock underperforms Monday when compared to competitors - MarketWatch

Mar 31, 2025

Sector Update: Health Care - MarketScreener

Mar 31, 2025

Mar 28, 2025

Inovio Pharmaceuticals Inc. stock underperforms Friday when compared to competitors - MarketWatch

Mar 28, 2025

Mar 26, 2025

Inovio stock plunges to 52-week low at $1.74 amid market challenges By Investing.com - Investing.com South Africa

Mar 26, 2025

Inovio stock plunges to 52-week low at $1.74 amid market challenges - Investing.com Australia

Mar 26, 2025

Mar 25, 2025

Lassa Fever Market Anticipated to Expand Rapidly During 2024-2034, Says DelveInsight | Inovio Pharma - Barchart.com

Mar 25, 2025

Mar 22, 2025

Inovio Pharmaceuticals, Inc. (NASDAQ:INO) Q4 2024 Earnings Call Transcript - Insider Monkey

Mar 22, 2025

Mar 21, 2025

INOVIO Reports Progress on INO-3107 and DNA Medicine, 2024 Financial Outcomes - MSN

Mar 21, 2025

Mar 20, 2025

Inovio Pharmaceuticals Inc. stock underperforms Thursday when compared to competitors - MarketWatch

Mar 20, 2025

Inovio’s SWOT analysis: dna firm’s stock faces crucial year ahead By Investing.com - Investing.com South Africa

Mar 20, 2025

DNA Vaccines Market and Their Impact on Global Health: Trends & - openPR.com

Mar 20, 2025

Mar 19, 2025

Inovio’s SWOT analysis: dna firm’s stock faces crucial year ahead - Investing.com

Mar 19, 2025

Inovio taking on Covid-19 again, almost 3 years after abandoning vaccine effort - Philadelphia Business Journal

Mar 19, 2025

Inovio aims for INO-3107 regulatory submission by mid-2025 while addressing key manufacturing issues - MSN

Mar 19, 2025

RBC Cuts Price Target on Inovio Pharmaceuticals to $5 From $6, Keeps Sector Perform, Speculative Risk - Marketscreener.com

Mar 19, 2025